Sierra Oncology, Inc. (SRRA) |
|
54.91 -0.04 (-0.07%)
|
06-26 23:03 |
|
Open: |
55.1 |
Pre. Close: |
54.95 |
|
High:
|
55.19 |
Low:
|
54.7 |
|
Volume:
|
2,379,048 |
Market Cap:
|
1,341(M) |
|
|
|
|
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
55.27 - 55.55 |
55.55 - 55.78 |
|
Low:
|
54.05 - 54.35 |
54.35 - 54.59 |
|
Close:
|
54.47 - 54.94 |
54.94 - 55.32 |
|
Technical analysis |
as of: 2022-06-24 4:43:24 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 64.46  One year: 75.29 |
| Support: |
Support1: 54.81 Support2: 54.58 |
| Resistance: |
Resistance1: 55.18 Resistance2: 64.46 |
| Pivot: |
54.9 |
| Moving Average: |
MA(5): 54.92 MA(20): 54.88
MA(100): 44.28 MA(250): 30.46 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.5 |
| Stochastic oscillator: |
%K(14,3): 42.2 %D(3): 46.7 |
| RSI: |
RSI(14): 75.7 |
| 52-week: |
High: 55.18 Low: 14.9 |
| Average Vol(K): |
3-Month: 624 (K) 10-Days: 452 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SRRA ] has closed below upper band by 42.7%. Bollinger Bands are 98.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sat, 25 Jun 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BKI, SAIL, SRRA, ATRS - GuruFocus.com
Tue, 21 Jun 2022
Is Sierra Oncology Inc (SRRA) Stock a Bad Value Tuesday? - InvestorsObserver
Fri, 17 Jun 2022
Sierra Oncology (SRRA) Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration - StreetInsider.com
Wed, 15 Jun 2022
Sierra Oncology (NASDAQ:SRRA) Reaches New 1-Year High at $56.62 - Defense World
Tue, 14 Jun 2022
Toronto Financial District Returning to Life With Covid Easing - Yahoo Finance
Wed, 01 Jun 2022
Pfizer Changes Its Mind, Will Sell Down Stake in GSK's Haleon Unit - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
15 (M) |
| Shares Float |
10 (M) |
|
% Held by Insiders
|
8.5 (%) |
|
% Held by Institutions
|
63 (%) |
|
Shares Short
|
1,010 (K) |
|
Shares Short P.Month
|
1,470 (K) |
Stock Financials |
|
EPS
|
-7.16 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.55 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-54.6 |
|
Return on Equity (ttm)
|
-97.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-3.99 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-6.27 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-79 (M) |
|
Levered Free Cash Flow
|
-43 (M) |
Stock Valuations |
|
PE Ratio
|
-7.67 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
8.37 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-10.47 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-01-22 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
